Matters

Pharmaceuticals

  • Sale of CyDex Pharmaceuticals, Inc. to Ligand Pharmaceuticals Incorporated
  • Sale of Planet Biopharmaceuticals, Inc. to Ares Allergy Holdings Inc.
  • Sale of Cedarburg Pharmaceuticals, Inc. to Albany Molecular Research, Inc. ($40+ million)
  • Represented an emerging anti-cancer company in a collaboration and license agreement with a major industry player followed by a restructure and sale of its assets
  • Represented an emerging company developing novel COX-2 inhibitors for the treatment of cancer in a collaboration and license agreement with an international health institute
  • Represented a generic pharmaceutical company in drafting invalidity opinions designed to precipitate a Hatch-Waxman proceeding.
  • Led due diligence projects for a multinational pharmaceutical and biopharmaceutical company, one of which resulted in their purchase of another biotechnology company for over one million dollars.
  • Provided IP counseling to a multibillion-dollar specialty biopharmaceutical company on number of potential drug and device acquisitions, including their publicly announced acquisitions of other entities in the medical space.
  • Served as outside patent counsel to branded and generic pharmaceutical companies, life sciences companies, and chemical companies in acquisitions involving products ranging from multimillion-dollar annual sales to multibillion-dollar annual sales.
  • Provided Hatch-Waxman defense for a global pharmaceutical company regarding a generic product for topical treatment of lice infestations, in addition to hydrocodone extended-release tablets.
  • Performed FTO analysis for generic versions of Humira and Erbitux for a basic life sciences research company.
  • Provided opinion counsel on design-around, non-infringement, and invalidity strategies in effort to assist the client in clearing the legal hurdles necessary to sales of lower priced generic versions of drugs in the U.S.
  • Drafted opinions for Paragraph IV ANDA disputes, including noninfringement and invalidity and representation in ANDA litigation

Vaccines

  • Purchase by the U.S. bioscience joint venture between two multinational technology companies of a controlling interest in a pandemic influenza manufacturing company from its university and state governmental founders
  • Represented a large company in advancing patent protections around the world for launch of a new vaccine directed to an unmet need.
  • Represented a large company in advancing patent protections around the world for advancement and clinical testing of a first vaccine against a rapidly spreading viral infection known to infect livestock and humans.

Medical Device

  • Represented Novita Therapeutics LLC in spinout and add-on venture financing of two medical device technologies into new medical device ventures, Metactive Medical, Inc. and Flow Forward Medical, Inc.
  • Sale of stock of medical device company Enturia Holding, Inc. to Cardinal Health, Inc.
  • Negotiated recapitalization transaction and venture capital financing transaction for medical device company in the prenatal NICU equipment space
  • Representation of a publicly traded micro-surgical instrument medical device company in establishing a strategic joint development agreement with a major national medical clinic
  • Multiple venture capital financings by Open Prairie Ventures and the Kansas BioScience Authority in Novita Therapeutics LLC
  • Performed patent due diligence on a target patent portfolio relating to various hemostasis products, including fibrin sealant compositions.
  • Prepared and prosecuted patents covering smart catheters and drug eluting stents.
  • Performed patentability and patent clearance analyses for a surgical clip/stapling system used for laparoscopic procedures.

Compounding Pharmacy

  • Sale of a major US compounding pharmacy to a leading European-based international compounding pharmacy conglomerate

Diagnostics

  • Sale of assets of Oncimmune (USA), LLC to Health Diagnostic Laboratory, Inc.
  • Represented a national diagnostics company in structuring and documenting multiple-site clinical trials on new diagnostic testing protocol with Mayo Clinic, Laureate Institute for Brain Research, Inc., The McLean Hospital Corporation and the University of Minnesota
  • Represented Beyond Battens Disease Foundation in negotiation of license for broad screening test for orphan pediatric diseases
  • Served as Special IP and regulatory counsel to a national diagnostics company in initial public securities offerings and follow-on offerings

Animal Health and Agriculture

  • Represented founders in formation and funding of TechAccel LLC, the first private capital, co-development partner focused on the acquisition and advancement of technologies in partnership with leading global companies in agriculture, animal health and food sectors
  • Served as special IP and regulatory counsel to Aratana Therapeutics, an animal-health biotech company, in initial public securities offering and follow-on offerings
  • Corporate restructuring, technology in-licensing transactions, and venture capital funding for Centaur Animal Health
  • Represented Australia’s leading animal health company in navigating U.S. regulatory hurdles, establishing a sales and distribution network and to enter the United States market
  • Represented a consortium of animal health manufacturers and distributors in transferring assets to, and acquiring new technology lines for, a new manufacturing and distribution system
  • Negotiated strategic partnerships and research and development agreements for TechAccel with Kansas State University
  • Structured angel investor funding and state tax credit program for initial investors in Aratana Therapeutics
  • Represented the interests of Kansas City Area Life sciences Institute and other of the world’s leading animal health companies in establishing the Center of Animal Health Innovation to help accelerate the development of early-stage animal health technologies

Plant Science

  • Facilitated the largest food-technology Series B financing to date. Polsinelli also represented this plant-based food company in their first round of financing and continues to serve as outside general counsel on an ongoing basis.
  • Sale of a leading ag-bio control company to Monsanto Company
  • Represented an emerging ag-bio company in a multimillion-dollar collaborative research and license agreement with a major crop sciences company

BioSecurity

  • Represented Kansas State University in matters relating to obtaining federal funding from the Department of Homeland Security for the construction of the $1.2 billion National Bio and Agro-Defense Facility, the nation’s newest federal laboratory located in Manhattan, Kansas